Effectiveness of TNF antagonists in routine clinical practice and costs
Authors:
M. Prokeš
Authors‘ workplace:
INFOPHARM a. s., Praha, ředitel PharmDr. Josef Suchopár
Published in:
Vnitř Lék 2009; 55(1): 45-53
Category:
Reviews
Overview
A comparison of effectiveness of TNF antagonists adalimumab, infliximab and etanercept in the treatment of rheumatoid arthritis (RA) was made, which was derived from studies provided abroad based on routine clinical practice. The calculation of cost‑effectiveness of each TNF antagonist for Czech Republic was made on the basis of Dutch DREAM registry of patients with RA (Kiewit et al, 2008). The prices of therapy of all three TNF antagonists are similar in the first year of treatment of patients with average weight, in the second year the price of infliximab is lower, but only in the case of patients where the doses do not reach 4 amp. of infliximab. Clinical effectiveness was evaluated in DAS28 and HAQ units. Cost‑effectiveness of all TNF antagonists was similar, when 2 amp. of infliximab per dose phycician considered sufficient, but when patients were given higher doses of infliximab the trend to lower cost‑effectiveness of infliximab compared to adalimumab and etanercept was observed.
Key words:
TNF antagonists – rheumatoid arthritis – cost‑effectiveness
Sources
1. Pavelka K, Rovenský J et al. Farmakoterapie revmatických onemocnění. Praha: Grada Publishing 2005: 181–215.
2. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. Health Qual Life Outcomes 2003; I: 20. http://www.hqlo.com/content/1/1/20.
3. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid artritis. N Eng J Med 2000; 343: 1594–1600.
4. Moreland LW, Weinblatt ME, Keystone EC et al. Etanercept Treatment in Adults with Established Rheumatoid Artritis: 7 Years of Clinical Experience. J Rheumatol 2006; 33: 854–861.
5. Weinblatt ME, Keystone EC, Furst DE et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65: 753–759.
6. Hyrich KM, Lung M, Watson KD et al. Outcomes After Switching From One Anti‑Tumor Nectrosis Factor α Agent in Patients With Rheumatoid Arthritis. Arthritis Rheum 2007; 56: 13–20.
7. Zink A, Strangfeld A, Schneider M et al. Effectiveness of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis in an Observational Cohort Study. Arthritis Rheumatism 2006; 54: 3399–3407.
8. Duclos M, Gossec L, Ruyssen-Witrand A et al. Retention Rates of Tumor Necrosis Factor Blockers in Daily Practice in 770 Rheumatic Patients. J Rheumatol 2006; 33: 2433–2439.
9. Finckh A, Simard JF, Gabay C et al. Evidence for differential acquired drug resistance to anti‑tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746–752.
10. Kievit W, Adang EM, Fransen HH et al. The effectiveness and medication costs of three anti‑TNF‑α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. ARD Online First, published on January 3, 2008, as 10.1136/ard.2007.083675.
11. Kolektiv autorů. Základy farmakoekonomiky pro lékaře, lékárníky a další pracovníky ve zdravotnictví. ČFES 2007.
12. Wailoo AJ, Bansback N, Brennan A et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost‑effectiveness analysis. Arhtritis Rheum 2008; 58: 939–946.
13. Brennan A, Bansback N, Noxon R et al. Modelling the cost effectiveness of THF‑alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007; 46: 1345–1354.
14. Breedveld FC, Weisman MH, Kavanaugh AF et al. A multucenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheumatism 2006; 54: 26–37.
15. Emery B, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375–382.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2009 Issue 1
Most read in this issue
- Adrenal cancer
- Coronary artery ectasia and triple-vessel disease
- Treatment of Waldenström macroglobulinaemia – the experience of one centre
- Cardiovascular rehabilitation today